Iovance Biotherapeutics (IOVA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 product revenue reached $121.469M, up 80% YoY; gross margin was a quarterly record of ~60%.
More than 1,000 U.S. commercial patients had received Amtagvi, and the authorized treatment-center network exceeded 100.
FY2026 revenue guidance remained $410M–$420M as registrational TIL programs advanced in NSCLC, sarcoma and melanoma.
Financial highlights
Q3 product revenue was $121.469M vs. $67.455M; 9M revenue was $292.212M vs. $176.731M.
Q3 net loss narrowed to $22.271M from $91.253M; diluted loss per share was $0.05 vs. $0.25.
Q3 operating loss was $23.968M vs. $94.901M; 9M operating loss was $156.916M vs. $329.896M.
Q3 R&D expense was $49.337M, down ~16% QoQ; SG&A was $38.6M.
Outlook and guidance
FY2026 product revenue guidance remained $410M–$420M; Q4 sequential revenue growth was expected.
Management expected cash runway well into 2029; the financial statements assessed available capital as sufficient for planned costs for at least 12 months after issuance.
IOV-LUN-202 Cohorts 1 and 2, targeting ~80 patients, were completing enrollment; a lifileucel sBLA was planned for 2027, subject to FDA discussions and review.
POSITILITY began enrollment in November 2026 with an 80-patient target; OPTILISM frontline biomarker-enriched NSCLC was planned for 2027.
Potential UK and Swiss Amtagvi approvals were expected in Q1 2027; EU application resubmission was planned for 2027.
Latest events from Iovance Biotherapeutics
- Revenue growth and 2027 lung, melanoma and sarcoma milestones drive the outlook.IOVA
Jefferies Global Healthcare Conference - Durable melanoma responses anchor a growing solid-tumor TIL pipeline.IOVA
Corporate presentation - Lifileucel achieved a 59.1% ORR in the biomarker-enriched mNSCLC subgroup.IOVA
Study update - Record revenue and strong clinical results drive expansion and innovation in TIL therapy.IOVA
H.C. Wainwright 28th Annual Global Investment Conference - Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook.IOVA
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue surged 66% to $99.3M, margin hit 56%, and cash reserves support ongoing growth.IOVA
Q2 2026 - Strong revenue growth and durable TIL therapy efficacy drive expansion in solid tumor oncology.IOVA
Corporate presentation - Five-year data confirm durable survival and expanding access for one-time TIL cell therapy in melanoma.IOVA
KOL event - Q1 2025 revenue was $49.3M; FY25 guidance is $250–$300M with global expansion underway.IOVA
Q1 2025